Statistics for A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609)
Total visits
| views | |
|---|---|
| A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609) | 2 |
Total visits per month
| views | |
|---|---|
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 0 |
| April 2025 | 0 |
| May 2025 | 0 |
| June 2025 | 0 |
| July 2025 | 0 |
File Visits
| views | |
|---|---|
| java.util.UUID:268a7aba-734d-448d-8f74-fc3326feba8a | 35 |
| java.util.UUID:1ca5def6-16f4-4029-b004-1ad066222e29 | 16 |
| Adams2022MultiCenter-AAM.pdf | 11 |
| java.util.UUID:f742f397-18ff-4375-8a1e-9245ca250a64 | 7 |
Top country views
| views | |
|---|---|
| United States | 2 |
Top city views
| views | |
|---|---|
| Greenwood | 2 |